Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (301-310 of 773) with videos related to

Pageof 78
Sort By:
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
The New England Journal of Medicine|March 31, 2006
Prevalence of monoclonal gammopathy of undetermined significanceRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
American Journal of Hematology|May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myelomaShaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
European Journal of Haematology|February 19, 2015
Clinical Course and Prognosis of Non-Secretory Multiple MyelomaSagar S Chawla, Shaji K Kumar, Angela Dispenzieri, et al.
European Journal of Haematology|November 11, 2014
Clinical course and prognosis of non-secretory multiple myelomaSagar S Chawla, Shaji K Kumar, Angela Dispenzieri, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
American Journal of Hematology|January 26, 2019
Tetraploidy is associated with poor prognosis at diagnosis in multiple myelomaSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Mayo Clinic Proceedings|August 4, 2009
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patientsJohn P Bida, Robert A Kyle, Terry M Therneau, et al.
Blood Cancer Journal|June 11, 2024
Performance of newer myeloma staging systems in a contemporary, large patient cohortGhulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kumar, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Pageof 78

Showing results (301-310 of 773) with videos related to

Sort By:
Pageof 78
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
The New England Journal of Medicine|March 31, 2006
Prevalence of monoclonal gammopathy of undetermined significanceRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
American Journal of Hematology|May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myelomaShaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
European Journal of Haematology|February 19, 2015
Clinical Course and Prognosis of Non-Secretory Multiple MyelomaSagar S Chawla, Shaji K Kumar, Angela Dispenzieri, et al.
European Journal of Haematology|November 11, 2014
Clinical course and prognosis of non-secretory multiple myelomaSagar S Chawla, Shaji K Kumar, Angela Dispenzieri, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
American Journal of Hematology|January 26, 2019
Tetraploidy is associated with poor prognosis at diagnosis in multiple myelomaSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Mayo Clinic Proceedings|August 4, 2009
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patientsJohn P Bida, Robert A Kyle, Terry M Therneau, et al.
Blood Cancer Journal|June 11, 2024
Performance of newer myeloma staging systems in a contemporary, large patient cohortGhulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kumar, et al.
The Lancet. Oncology|October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialS Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Pageof 78